Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress

Zongmin Zhou, Anastasia Pyriochou, Anastasia Kotanidou, Georgios Dalkas, Martin Van Eickels, Georgios Spyroulias, Charis Roussos, Andreas Papapetropoulos

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Many vascular diseases are characterized by increased levels of ROS that destroy the biological activity of nitric oxide and limit cGMP formation. In the present study, we investigated the cGMP-forming ability of HMR-1766 in cells exposed to oxidative stress. Pretreatment of smooth muscle cells with H 2O2 reduced cGMP production stimulated by sodium nitroprusside (SNP) or BAY 41-2272. However, pretreatment with H 2O2 significantly increased HMR-1766 responses. Similar results were obtained with SIN-1, menadione, and rotenone. In addition, HMR-1766 was more effective in stimulating heme-free sGC compared with the wild-type enzyme. Interestingly, in cells expressing heme-free sGC, H2O 2 inhibited instead of potentiated HMR-1766 responses, suggesting that the ROS-induced enhancement of cGMP formation was heme dependent. Moreover, using truncated forms of sGC, we observed that the NH2-terminus of the β1-subunit is required for the action of HMR-1766. Finally, to study tolerance development to HMR-1766, cells were pretreated with this sGC activator and reexposed to HMR-1766 or SNP. Results from these experiments demonstrated lack of tolerance development to HMR-1766 as well as lack of cross-tolerance with SNP. We conclude that HMR-1766 is an improved sGC activator as it has the ability to activate oxidized/heme-free sGC and is resistant to the development of tolerance; these observations make HMR-1766 a promising agent for treating diseases associated with increased vascular tone combined with enhanced ROS production.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume295
Issue number4
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Oxidative Stress
Heme
Nitroprusside
Soluble Guanylyl Cyclase
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide
Vitamin K 3
Rotenone
Vascular Diseases
Smooth Muscle Myocytes
Blood Vessels
Nitric Oxide
Enzymes

Keywords

  • cGMP
  • Nitric oxide
  • Reactive oxygen species
  • Soluble guanylyl cyclase

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. / Zhou, Zongmin; Pyriochou, Anastasia; Kotanidou, Anastasia; Dalkas, Georgios; Van Eickels, Martin; Spyroulias, Georgios; Roussos, Charis; Papapetropoulos, Andreas.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 295, No. 4, 01.10.2008.

Research output: Contribution to journalArticle

Zhou, Zongmin ; Pyriochou, Anastasia ; Kotanidou, Anastasia ; Dalkas, Georgios ; Van Eickels, Martin ; Spyroulias, Georgios ; Roussos, Charis ; Papapetropoulos, Andreas. / Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. In: American Journal of Physiology - Heart and Circulatory Physiology. 2008 ; Vol. 295, No. 4.
@article{713ac61723a240ab89eccd04108f3648,
title = "Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress",
abstract = "Many vascular diseases are characterized by increased levels of ROS that destroy the biological activity of nitric oxide and limit cGMP formation. In the present study, we investigated the cGMP-forming ability of HMR-1766 in cells exposed to oxidative stress. Pretreatment of smooth muscle cells with H 2O2 reduced cGMP production stimulated by sodium nitroprusside (SNP) or BAY 41-2272. However, pretreatment with H 2O2 significantly increased HMR-1766 responses. Similar results were obtained with SIN-1, menadione, and rotenone. In addition, HMR-1766 was more effective in stimulating heme-free sGC compared with the wild-type enzyme. Interestingly, in cells expressing heme-free sGC, H2O 2 inhibited instead of potentiated HMR-1766 responses, suggesting that the ROS-induced enhancement of cGMP formation was heme dependent. Moreover, using truncated forms of sGC, we observed that the NH2-terminus of the β1-subunit is required for the action of HMR-1766. Finally, to study tolerance development to HMR-1766, cells were pretreated with this sGC activator and reexposed to HMR-1766 or SNP. Results from these experiments demonstrated lack of tolerance development to HMR-1766 as well as lack of cross-tolerance with SNP. We conclude that HMR-1766 is an improved sGC activator as it has the ability to activate oxidized/heme-free sGC and is resistant to the development of tolerance; these observations make HMR-1766 a promising agent for treating diseases associated with increased vascular tone combined with enhanced ROS production.",
keywords = "cGMP, Nitric oxide, Reactive oxygen species, Soluble guanylyl cyclase",
author = "Zongmin Zhou and Anastasia Pyriochou and Anastasia Kotanidou and Georgios Dalkas and {Van Eickels}, Martin and Georgios Spyroulias and Charis Roussos and Andreas Papapetropoulos",
year = "2008",
month = "10",
day = "1",
doi = "10.1152/ajpheart.51.2008",
language = "English (US)",
volume = "295",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress

AU - Zhou, Zongmin

AU - Pyriochou, Anastasia

AU - Kotanidou, Anastasia

AU - Dalkas, Georgios

AU - Van Eickels, Martin

AU - Spyroulias, Georgios

AU - Roussos, Charis

AU - Papapetropoulos, Andreas

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Many vascular diseases are characterized by increased levels of ROS that destroy the biological activity of nitric oxide and limit cGMP formation. In the present study, we investigated the cGMP-forming ability of HMR-1766 in cells exposed to oxidative stress. Pretreatment of smooth muscle cells with H 2O2 reduced cGMP production stimulated by sodium nitroprusside (SNP) or BAY 41-2272. However, pretreatment with H 2O2 significantly increased HMR-1766 responses. Similar results were obtained with SIN-1, menadione, and rotenone. In addition, HMR-1766 was more effective in stimulating heme-free sGC compared with the wild-type enzyme. Interestingly, in cells expressing heme-free sGC, H2O 2 inhibited instead of potentiated HMR-1766 responses, suggesting that the ROS-induced enhancement of cGMP formation was heme dependent. Moreover, using truncated forms of sGC, we observed that the NH2-terminus of the β1-subunit is required for the action of HMR-1766. Finally, to study tolerance development to HMR-1766, cells were pretreated with this sGC activator and reexposed to HMR-1766 or SNP. Results from these experiments demonstrated lack of tolerance development to HMR-1766 as well as lack of cross-tolerance with SNP. We conclude that HMR-1766 is an improved sGC activator as it has the ability to activate oxidized/heme-free sGC and is resistant to the development of tolerance; these observations make HMR-1766 a promising agent for treating diseases associated with increased vascular tone combined with enhanced ROS production.

AB - Many vascular diseases are characterized by increased levels of ROS that destroy the biological activity of nitric oxide and limit cGMP formation. In the present study, we investigated the cGMP-forming ability of HMR-1766 in cells exposed to oxidative stress. Pretreatment of smooth muscle cells with H 2O2 reduced cGMP production stimulated by sodium nitroprusside (SNP) or BAY 41-2272. However, pretreatment with H 2O2 significantly increased HMR-1766 responses. Similar results were obtained with SIN-1, menadione, and rotenone. In addition, HMR-1766 was more effective in stimulating heme-free sGC compared with the wild-type enzyme. Interestingly, in cells expressing heme-free sGC, H2O 2 inhibited instead of potentiated HMR-1766 responses, suggesting that the ROS-induced enhancement of cGMP formation was heme dependent. Moreover, using truncated forms of sGC, we observed that the NH2-terminus of the β1-subunit is required for the action of HMR-1766. Finally, to study tolerance development to HMR-1766, cells were pretreated with this sGC activator and reexposed to HMR-1766 or SNP. Results from these experiments demonstrated lack of tolerance development to HMR-1766 as well as lack of cross-tolerance with SNP. We conclude that HMR-1766 is an improved sGC activator as it has the ability to activate oxidized/heme-free sGC and is resistant to the development of tolerance; these observations make HMR-1766 a promising agent for treating diseases associated with increased vascular tone combined with enhanced ROS production.

KW - cGMP

KW - Nitric oxide

KW - Reactive oxygen species

KW - Soluble guanylyl cyclase

UR - http://www.scopus.com/inward/record.url?scp=57049114424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049114424&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.51.2008

DO - 10.1152/ajpheart.51.2008

M3 - Article

VL - 295

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 4

ER -